Acute interstitial lung disease in a patient with anaplastic lymphoma kinase-positive non-small-cell lung cancer after crizotinib therapy

Crizotinib, an orally active multi-targeted small-molecule anaplastic lymphoma kinase (ALK) inhibitor, is an effective treatment modality for advanced ALK-positive non-small-cell lung cancer (NSCLC). Most drug-related adverse events are mild to moderate; however, some patients may develop acute inte...

Descripción completa

Detalles Bibliográficos
Autores principales: Maka, Vinayak V., Krishnaswamy, Uma Maheshwari, Anil Kumar, N., Chitrapur, Rohith, Kilara, Nalini
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2014
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4369967/
https://www.ncbi.nlm.nih.gov/pubmed/25988009
http://dx.doi.org/10.1093/omcr/omu004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4369967/
https://www.ncbi.nlm.nih.gov/pubmed/25988009
http://dx.doi.org/10.1093/omcr/omu004

Ejemplares similares